Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease

NCT07753200 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

3000

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation (AF)
Coronary Arterial Disease (CAD)

Interventions

DRUG: Edoxaban
DRUG: Apixaban

Sponsor

Samsung Medical Center